ReviewStem cell research & therapy2026
Advances in retinal pigment epithelium transplantation for age-related macular degeneration: bridging biology to therapeutic frontiers.
Review in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stem cell-derived RPE replacement is a potential therapeutic for advanced AMD that is characterized by macular scarring and geographic atrophy leading to severe vision loss. Although the field of stem cell-differentiated RPE transplantation has undergone significant evolution, important gaps in our knowledge remains unaddressed. Long-term RPE cell survival and integration into the neural retina post-transplantation has yet to be established. Employing advanced imaging techniques and transcriptomics to study cellular integration and immune tolerance post-transplant, will improve our understanding. In addition, a better understanding of RPE bioenergetics, in the context of cell therapy, is crucial for developing more effective therapeutics. This is especially important for stem cell therapy, typically derived from varying somatic cells of origin, with inherently distinct metabolic profiles. This review focuses on current approaches to improve the outcomes of RPE transplantation, and thereby facilitate robust development of retinal cell therapy, to address the unmet clinical needs of patients with advanced AMD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.